2025AHA热点聚焦：12场特色科学研究专场，72项重磅研究集结，解锁心血管诊疗新证据

当地时间2025年11月7日- 10日，全球心血管领域顶级学术盛会—— 美国心脏协会科学年会（2024 AHA）将在新奥尔良重磅召开，为全球医者打造沉浸式学术交流平台。作为大会核心亮点，组委会精心设置12场“特色科学研究（Featured Science）专场”，届时将集中发布72项具有里程碑意义的心血管临床研究成果，涵盖肥厚型心肌病（HCM）、动静脉疾病、心力衰竭、人工智能（AI ）在心血管领域的应用等关键领域，为全球医者呈现兼具创新性与临床价值的研究成果，助力心血管疾病诊疗升级。

HCMS.FS 肥厚型心肌病（HCM）特色科学研究专场

北京时间：11月8日7:00

Effect of Mavacamten on Measures of Cardiopulmonary Exercise Testing: An Analysis of the ODYSSEY-HCM Randomized Trial

ODYSSEY-HCM随机试验再分析：玛伐凯泰对心肺运动测试指标的影响

Polygenic Risk Enhances Penetrance and Prognosis in Hypertrophic Cardiomyopathy: Insights from a US-based Multi-Ancestry Cohort

基于美国多种族队列的研究洞见：多基因风险增强HCM外显率及对预后的影响

MAPLE-HCM - Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy

MAPLE-HCM试验：Aficamten vs 美托洛尔单药，对梗阻性HCM患者报告健康状态的影响

ODYSSEY-HCM - Effect of selected baseline characteristics and exposure on efficacy and safety of mavacamten: A Post-Hoc Analysis from the ODYSSEY trial

ODYSSEY试验事后分析：基线特征与药物暴露量对玛伐凯泰疗效和安全性的影响

FS.01 动静脉困境：静脉血栓栓塞（VTE）与外周动脉疾病（PAD）

北京时间：11月8日 22:45

ROXI – Two Mechanistically Distinct Factor XI Antibodies, REGN9933 and REGN7508, for the Prevention of Venous Thromboembolism After Knee Arthroplasty: the ROXI-VTE-I and ROXI-VTE-II trials

ROXI-VTE-I 和ROXI-VTE-II试验：两种作用机制不同的FXI抗体（REGN9933与REGN7508）用于膝关节置换术后静脉血栓栓塞预防

PERMET – Metformin for walking impairment in peripheral artery disease: The PERMET Randomized Clinical Trial

PERMET随机临床试验：二甲双胍能否用于改善PAD患者的步行功能障碍

Foot-PAD – A Double-Blind, Randomized Placebo-Controlled Trial to determine the effect of a 12-Week Program of Footplate Neuromuscular Electrical Stimulation on Walking Capacity in Patients with Peripheral Artery Disease

Foot-PAD双盲、随机、安慰剂对照试验（12周）：评估足底神经肌肉电刺激对PAD患者步行能力的影响

DART – DDCI-01 in Pulmonary Arterial Hypertension: A Multicenter Phase IIa Randomized Active-Controlled Trial

DART IIa期多中心、随机活性对照试验：DDCI-01用于肺动脉高压的治疗

SATISFY-JP Trial – Satralizumab, an Anti-Interleukin-6 Receptor Antibody, for Pulmonary Arterial Hypertension with an Activated Immune-Responsive Phenotype: Primary Results from the Phase II Trial

SATISFY-JP II期试验主要结果：抗IL-6受体抗体Satralizumab用于免疫反应表型激活的肺动脉高压治疗的安全性和有效性

PULSAR, STELLAR, ZENITH - Effect of Sotatercept on Mortality and Major Morbidity Outcomes in Patients with Pulmonary Arterial Hypertension: Pooled Analysis of the PULSAR, STELLAR, and ZENITH Trials

PULSAR、STELLAR、ZENITH试验汇总分析：Sotatercept对肺动脉高压患者死亡率和主要发病率的影响

RESCUE-PTTM – Efficacy and Safety of Imatinib Therapy Administered in Patients with Pulmonary Tumor Thrombotic Microangiopathy (PTTM) : A Prospective, Multi-Center Exploratory Clinical Trial

RESCUE-PTTM前瞻性、多中心、探索性试验：伊马替尼治疗肺肿瘤血栓性微血管病（PTTM）的安全性和有效性

FS.02 从马德里到新奥尔良：游行中的心衰试验

北京时间：11月9日 02:30

Get with the Guidelines Hospital Participation and its Impact on GDMT and HF Outcomes using an Interrupted Time Series Analysis *

中断时间序列分析*：指南依从性医院参与度及其对指南指导药物治疗（GDMT）和心衰结局的影响

DIGIT-HF – Efficacy and safety of Digitoxin in heart failure with reduced ejection fraction according to age: Insights from DIGIT-HF *

DIGIT-HF试验再分析：洋地黄毒苷在射血分数降低的心衰（HFrEF）患者中的疗效和安全性（按年龄分层分析）*

MAPLE-HCM – Clinical Responses to Aficamten Monotherapy Compared with Metoprolol for Obstructive Hypertrophic Cardiomyopathy Outcomes and Disease Burden: MAPLE-HCM Responder Analysis

MAPLE-HCM应答分析试验：Aficamten vs美托洛尔单药治疗，对HCM结局与疾病负担的临床反应

DAPA ACT HF-TIMI 68 – Blood Pressure and Symptomatic Hypotension with Dapagliflozin vs. Placebo in Patients Hospitalized with Heart Failure

DAPA ACT HF-TIMI 68试验：达格列净vs安慰剂，对心衰住院患者血压及症状性低血压的影响

SOTA-P-CARDIA Trial (ATRU-V) – A Randomized Trial of Sotagliflozin in HFpEF patients without diabetes *

SOTA-P-CARDIA（ATRU-V）随机试验*：索格列净用于无糖尿病的射血分数保留的心衰（HFpEF）患者的疗效和安全性

SURPASS-CVOT – Effects of Sodium-Glucose Cotransporter-2 Inhibitor Use on Major Adverse Cardiovascular Events in Participants With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease Treated With Tirzepatide Versus Dulaglutide *

SURPASS-CVOT试验*：替尔泊肽vs度拉鲁肽，对2型糖尿病合并动脉粥样硬化性心血管疾病（ASCVD）患者主要不良心血管事件的影响

FS.03 人工智能在心血管领域的试验与应用

北京时间：11月9日 04:15

DETECT-HF – Multicenter Clinical Study of Remote Speech Analysis to Detect Worsening Heart Failure: Results of the Pivotal DETECT-HF Trial *

DETECT-HF关键性试验结果*：远程语音分析检测心衰恶化的多中心临床研究

DAMSUN-HF – Prospective Validation and Real-World Implementation of an AI-Enabled Digital Stethoscope for Detecting Systolic Dysfunction in Low-Resource Settings

DAMSUN-HF试验：AI数字听诊器在低资源环境检测收缩功能不全的前瞻性验证与真实世界应用

Improved Identification of Near-Term Heart Failure Risk in Pooled Cohort Studies Using ECG-AI and PREVENT-HF

在基于ECG-AI与PREVENT-HF的多队列研究汇总分析中，优化近期心衰风险的识别

ECG2Stroke – ECG deep learning model accurately predicts ischemic stroke risk*

ECG2Stroke试验*：利用心电图深度学习模型精准预测缺血性卒中风险

Accuracy of cardiologist reporting of severe aortic stenosis and its impact on clinical management: Insights from decision-support artificial intelligence applied to 28,491 men and women undergoing echocardiography*

基于28491例接受超声心动图检查患者的AI决策支持应用洞见 *：AI决策系统对心脏病专家报告的严重主动脉瓣狭窄的准确性及其对临床管理的影响

FS.04 心衰生物性与实用性干预：从当下到未来

北京时间：11月9日21:00

ANSWER-HF – A Randomized Controlled Trial of Sacubitril/Valsartan Versus Enalapril in Patients with Chronic Chagas Cardiomyopathy and Reduced Ejection Fraction

ANSWER-HF随机对照试验：沙库巴曲缬沙坦vs 依那普利，治疗慢性恰加斯心肌病伴射血分数降低患者的疗效和安全性

DAPA-EAT – Dapagliflozin Reduces Epicardial Adipose Tissue and Myocardial Fibrosis in Subclinical Heart Failure: The DAPA-EAT Trial

DAPA-EAT试验：达格列净减少亚临床心衰患者的心外膜脂肪与心肌纤维化

MAPLE-HCM – Effect of Aficamten versus Metoprolol Monotherapy on Biomarkers in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Trial

MAPLE-HCM试验：Aficamten vs美托洛尔单药治疗，对梗阻性HCM生物标志物的影响

First-in-Human Gene Therapy Trial for Patients with Heart Failure with preserved Ejection Fraction (HFpEF) MUSIC-HFpEF: Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction *

MUSIC-HFpEF首次人体基因治疗试验：SERCA2a调控治疗HFpEF*

BioVAT-HF DZHK20 – Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure - BioVAT-HF-DZHK20 – Phase II Interim Data Report *

BioVAT-HF DZHK20 II期试验中期数据报告*：诱导多能干细胞衍生工程的人心肌组织作为终末期心衰生物心室辅助组织的安全性和有效性

COPILOT HF – Main Results of the Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure (COPILOT-HF) Program – A Pragmatic Randomized Study

COPILOT HF实用性随机试验：心衰最佳治疗协同实施合作项目的主要结果

FS.05 冠心病的药物与介入治疗进展

北京时间：11月9日 22:15

TARGET-D – A Randomized Clinical Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Acute Coronary Syndrome Patients: The TARGET-D Trial

TARGET-D随机临床试验：维生素D水平正常化对急性冠脉综合征（ACS）患者主要不良心血管事件的影响

ICare-FASTER – Improving Care by Faster Risk-Stratification with High-Sensitivity Point-of-Care Troponin in Patients in the Emergency Department: A Stepped-Wedge Cluster Randomised Trial

ICare-FASTER随机试验：急诊高危患者应用床旁高敏肌钙蛋白进行快速风险分层以改善护理的阶梯楔形整群随机试验

Heart Matters – The effectiveness of heart attack education in regions at highest-risk – the Heart Matters Stepped-Wedge Randomized Control Trial

Heart Matters试验：高风险地区心梗健康教育有效性的阶梯楔形随机对照试验

iSENSE-ACS – Infrared Sensor Evaluation for Noninvasive Screening and Early triage in Acute Coronary Syndromes: The iSENSE-ACS Multicenter Study

iSENSE-ACS多中心试验：利用红外传感技术进行ACS无创筛查与早期分诊

CRTC – An individual patient data meta-analysis of complete versus culprit-lesion only revascularization for acute myocardial infarction involving >8,800 individuals: The Complete Revascularization Trialists’ Collaboration (CRTC) *

CRTC荟萃分析*：在＞8800例急性心梗患者中，比较完全血运重建与仅处理罪犯病变策略的疗效和安全性

FAMOUS – Long-term follow-up of patients with multivessel coronary artery disease – comparison between Functional, Anatomical, or Medical Only-based Evaluation to Prevent Cardiovascular Events – The FAMOUS Trial

FAMOUS 多支冠脉病变患者的长期随访试验：基于功能学、解剖学或单纯药物治疗的评估策略，对预防心血管事件的影响

Beta-Blocker Therapy After Myocardial Infarction in Patients with Preserved Left Ventricular Ejection Fraction: An Individual Patient Data Meta-Analysis of Randomized Controlled Trials (REBOOT, REDUCE-AMI, BETAMI, DANBLOCK, CAPITAL-RCT)

多项随机对照试验的荟萃分析：心梗后射血分数保留患者进行β受体阻滞剂治疗的疗效和安全性

NEO-MINDSET – Early Aspirin Withdrawal after Percutaneous Coronary Intervention in Acute Coronary Syndromes With and Without ST-Segment Elevation: Results from the NEO-MINDSET trial

NEO-MINDSET试验结果：ST段抬高型与非ST段抬高型ACS患者在经皮冠脉介入治疗（PCI）后早期停用阿司匹林的疗效和安全性

FS.06 泛血管介入：跨血管床解剖与介入治疗

北京时间：11月10日 00:50

J-BPA–Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: A Nationwide Prospective Multicenter Registry in Japan

J-BPA日本全国前瞻性多中心注册研究：球囊肺动脉成形术治疗慢性血栓栓塞性肺动脉高压的疗效和安全性

FAIR– Fractional Flow Reserve-guided Renal Artery Stenting in Atherosclerotic Renovascular Hypertension: 1 Year Results of the FAIR Randomized Trial

FAIR随机试验1年结果：血流储备分数（FFR）指导的肾动脉支架置入治疗动脉粥样硬化性肾血管性高血压的疗效和安全性

COACT–Coronary Angiography After Cardiac Arrest Without ST-Segment Elevation: Five-Year Outcomes *

COACT试验5年随访结局*：心脏骤停后非ST段抬高患者的冠状动脉造影评估

OPTIMAL– Prospective, multicenter, open-label, randomized controlled trial of deferred stenting versus prompt stenting in acute occlusion of left main coronary artery: Primary outcomes of the OPTIMAL trial *

OPTIMAL试验主要结果*：左主干急性闭塞延期支架置入与即刻支架置入策略的前瞻性、多中心、开放标签、随机对照试验

SCAPIS– Coronary CT Angiography in Prediction of Coronary Events *

SCAPIS试验*：探究冠状动脉计算机断层扫描血管造影（CCTA）对冠脉事件的预测价值

MUSHY PEAS– Coronary CT Angiography Plaque as a Predictor of Death, Cardiovascular Death and Myocardial Infarction *

MUSHY PEAS试验*：冠状动脉CT斑块对死亡、心血管死亡和心梗的预测作用

CONFIRM2– Risk stratification by AI-guided CT coronary atherosclerosis quantification alongside the clinical likelihood of obstructive stenosis. (CONFIRM2)

CONFIRM2试验：AI指导的CT冠状动脉粥样硬化量化联合临床可能性进行风险分层

FS.07 心脏代谢综合征管理的新机遇

北京时间：11月10日 04:15

SPRINT– Arterial Stiffness Mechanisms and Orthostatic Hypotension in The Systolic Blood Pressure Intervention Trial *

SPRINT试验*：动脉僵硬度机制与体位性低血压

KARDIA-3– A randomized trial of zilebesiran versus placebo on top of standard care for patients with hypertension and established cardiovascular disease or high cardiovascular risk with or without chronic kidney disease

KARDIA-3试验：在进行标准治疗的伴或不伴慢性肾病的合并心血管疾病或心血管疾病高危的高血压患者中，对比Zilebesiran与安慰剂的疗效和安全性

Bax24– Effect of Baxdrostat on 24-Hour Average Ambulatory Blood Pressure in Patients with Resistant Hypertension: The Bax24 Trial

Bax24试验：探究进行Baxdrostat治疗对耐药性高血压患者24小时平均动态血压的影响

SURPASS-CVOT– Once-weekly tirzepatide versus dulaglutide on major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease

SURPASS-CVOT试验：替尔泊肽vs度拉糖肽（每周一次），对2型糖尿病合并心血管疾病患者主要不良心血管事件的影响

TIRZSEMA-CVOT– Cardiovascular Outcomes for Tirzepatide and Semaglutide: A RCT-DUPLICATE Initiative

TIRZSEMA-CVOT试验：替尔泊肽vs司美格鲁肽的心血管结局（RCT-DUPLICATE倡议）

CORALreef HeFH– Enlicitide, an oral PCSK9 inhibitor, in participants with heterozygous familial hypercholesterolemia: a double-blind, Phase 3, randomized placebo-controlled trial

CORALreef HeFH双盲、III期、随机、安慰剂对照试验：探究口服PCSK9抑制剂Enlicitide治疗杂合子家族性高胆固醇血症的疗效和安全性

LIBerate-OLE– Long-term Efficacy and Safety of Lerodalcibep in the Open-label 72-week Extension Study of Subjects Previously on Inclisiran or Lerodalcibep in the LIBerate-VI Trial (LIBerate-OLE)

LIBerate-OLE试验：Lerodalcibep在LIBerate-VI试验后的72周开放标签扩展研究中的长期疗效和安全性

ELM– Lifestyle intervention for sustained remission of metabolic syndrome (ELM: Enhanced Lifestyles in the Metabolic Syndrome)

ELM试验（代谢综合征促进强化生活方式干预试验）：探究生活方式干预能否促进代谢综合征持续缓解

FS.08 电生理特色科学领域

北京时间：11月10日 21:00

PFA-SHAM– Pulsed Field Ablation versus Sham Ablation to Treat Atrial Fibrillation

PFA-SHAM试验：脉冲场消融vs假消融，治疗心房颤动

MANIFEST-US– Multicenter Study on the Safety of Pulsed Field Ablation in the United States

MANIFEST-US多中心试验：在美国患者中，探究脉冲场消融的安全性

Strength-Based Exercise is Not Associated with Risk of Ventricular Arrhythmia in Arrhythmogenic Cardiomyopathy – Towards Safer Exercise Options

探索更安全的运动选择：力量训练与致心律失常性心肌病患者的室性心律失常风险无关

Artificial Intelligence Analysis of the 12-lead ECG and Clinical Factors to Predict Out-of-Hospital Cardiac Arrest

结合AI分析的12导联心电图与临床因素预测院外心脏骤停

ACE-PAS– Primary Results from the Post Approval Study of a Next Generation Wearable Cardioverter Defibrillator System: the ACE-PAS Trial

ACE-PAS试验：新一代可穿戴心脏除颤系统获批后研究的主要结局

FLECA-ED– Efficacy and safety of flecainide compared to amiodarone for atrial fibrillation cardioversion in patients with Coronary Artery Disease and preserved ejection fraction

FLECA-ED试验：氟卡尼vs胺碘酮，用于冠脉疾病合并射血分数保留患者房颤复律的安全性与有效性

FS.09 流感与新冠科学领域

北京时间：11月11日 02:00

High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes: The FLUNITY-HD Pooled Analysis*

FLUNITY-HD汇总分析*：高剂量vs 标准剂量流感疫苗对心血管结局的影响

KP-VACCINATE- Impact of Cardiovascular-Focused Messaging to Improve Influenza Vaccination on Cardiovascular-Kidney-Metabolic Care Patterns and Clinical Outcomes: Insights from the KP VACCINATE Megatrial

来自KP-VACCINATE大型试验的洞见：以心血管为重点的宣教可改善流感疫苗接种对心血管-肾脏-代谢护理模式与临床结局的影响

DAN-GAL-FLU - Effectiveness of High-Dose vs. Standard-Dose Inactivated Influenza Vaccine in Individuals with and without Atherosclerotic Cardiovascular Disease: A Pooled FLUNITY-HD Trial Analysis (DAN-GAL-FLU (DANFLU-2 and GALFLU))

FLUNITY-HD试验汇总分析（DAN-GAL-FLU试验[DANFLU-2和GALFLU]）：高剂量 vs. 标准剂量灭活流感疫苗在ASCVD患者中的有效性

NUDGE-FLU-CHRONIC- Influenza vaccination and risk of cardiovascular events: An instrumental variable analysis of >600,000 participants from the NUDGE-FLU-CHRONIC 1 and 2 trials

NUDGE-FLU-CHRONIC试验：流感疫苗接种与心血管事件风险——基于NUDGE-FLU-CHRONIC 1和2试验中超过60万参与者的工具变量分析

CISCO-21- Resistance Exercise Therapy After COVID-19 Infection: a Randomized, Controlled Trial *

CISCO-21试验 *：COVID-19感染后抗阻运动治疗的随机对照试验

FS.10 重构心脏淀粉样变诊疗方案：新型识别、治疗和治愈手段

北京时间：11月11日 02:30

AI-SCREEN-CA- Artificial Intelligence-based Software for Checking REal-world Echocardiography to ideNtify hidden Cardiac Amyloidosis: AI-SCREEN-CA *

AI-SCREEN-CA试验*：基于AI的实时超声心动图检测软件，或有助于识别隐匿性心脏淀粉样变

Improving Detection of Transthyretin Cardiac Amyloidosis with AI: A Single-Arm Multicenter Trial*

单臂多中心试验*：AI或可改善转甲状腺素蛋白心脏淀粉样变性（ATTR-CM）的检测

ATTR-CM- Primary results from the phase 2 randomized, placebo controlled, blinded trial of the monoclonal antibody coramitug in transthyretin amyloid cardiomyopathy *

ATTR-CM II期随机、安慰剂、对照、盲法试验主要结果*：单克隆抗体Coramitug治疗转甲状腺素蛋白淀粉样心肌病的疗效和安全性

Updated Phase 1 Clinical Trial Outcomes of CRISPR Gene Editing With Nexiguran Ziclumeran In Patients With Transthyretin Amyloidosis With Cardiomyopathy

CRISPR基因编辑疗法Nexiguran Ziclumeran治疗转甲状腺素蛋白淀粉样变性心肌病的I期临床试验更新结果

FS.11 脂质治疗：从转化到应用

北京时间：11月11日04:15

SHR-1918, an Angiopoietin-Like 3 Antibody, in Patients With Suboptimally Controlled Hyperlipidemia*

血管生成素样蛋白3（ANGPTL3）抗体SHR-1918用于血脂控制不佳患者*

Dose-Dependent and Sustained Reduction in Lipoprotein(a) levels after single-dose of Kylo-11, a LPA-targeted Small Interfering RNA, in Healthy Volunteers: A First-in-Human Phase I Study

首次人体I期研究：健康志愿者在注射单剂量LPA靶向siRNA药物Kylo-11后，脂蛋白(a)呈剂量依赖性持续降低

Evolocumab and Saphenous Vein Graft Patency Following Coronary Artery Bypass Graft (CABG) Surgery in People with and without Diabetes: A Pre-Specified Analysis of the Randomized Placebo Controlled NEWTON-CABG CardioLink-5 Trial

NEWTON-CABG CardioLink-5随机安慰剂对照试验预设分析：依洛尤单抗对糖尿病患者和非糖尿病患者CABG术后大隐静脉桥通畅率的影响

Effects of Real-Time Notification of AI-Derived Incidental Coronary Artery Calcium on Statin Initiation: the Trial *

NOTIFY-PICTURE试验*：AI衍生的偶发冠状动脉钙（CAC）实时通知对他汀类药物启动的影响

A Novel Approach to Manage Hypercholesterolemia: The Veterans Affairs Lipid Optimization Reimagined Quality Improvement (VALOR-QI) Program*

退伍军人事务部血脂优化重塑质量改进项目（VALOR-QI）*：高胆固醇血症管理新方法

Refining ASCVD Risk Stratification Using a Lipid-Derived Index: Multi-Cohort Evidence Beyond Guideline Thresholds

超越指南阈值的多队列证据：基于脂质衍生指标优化ASCVD风险分层

注：*已接收未确认的研究

信源：AHA 官网

医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。